Research priorities for an HIV cure: international AIDS society global scientific strategy 2021
Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …
treatment is required and there is no cure. HIV can integrate in the host genome and persist …
Getting the “kill” into “shock and kill”: strategies to eliminate latent HIV
Y Kim, JL Anderson, SR Lewin - Cell host & microbe, 2018 - cell.com
Despite the success of antiretroviral therapy (ART), there is currently no HIV cure and
treatment is life long. HIV persists during ART due to long-lived and proliferating latently …
treatment is life long. HIV persists during ART due to long-lived and proliferating latently …
Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
CC Nixon, M Mavigner, GC Sampey, AD Brooks… - Nature, 2020 - nature.com
Long-lasting, latently infected resting CD4+ T cells are the greatest obstacle to obtaining a
cure for HIV infection, as these cells can persist despite decades of treatment with …
cure for HIV infection, as these cells can persist despite decades of treatment with …
Targeting the latent reservoir for HIV-1
S Sengupta, RF Siliciano - Immunity, 2018 - cell.com
Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …
AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques
The main barrier to HIV cure is a persistent reservoir of latently infected CD4+ T cells
harboring replication-competent provirus that fuels rebound viremia upon antiretroviral …
harboring replication-competent provirus that fuels rebound viremia upon antiretroviral …
Curing HIV: seeking to target and clear persistent infection
Human immunodeficiency virus type 1 (HIV-1) infection persists despite years of
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …
antiretroviral therapy (ART). To remove the stigma and burden of chronic infection …
HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment
HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV)
infection, with increased levels of HBV DNA, accelerated progression of liver disease and …
infection, with increased levels of HBV DNA, accelerated progression of liver disease and …
Application of marine natural products in drug research
WY Lu, HJ Li, QY Li, YC Wu - Bioorganic & medicinal chemistry, 2021 - Elsevier
New diseases are emerging as the environment changes, so drug manufacturers are always
on the lookout for new resources to develop effective and safe drugs. In recent years, many …
on the lookout for new resources to develop effective and safe drugs. In recent years, many …
HIV “shock and kill” therapy: In need of revision
The implementation of antiretroviral therapy 23 years ago has rendered HIV infection
clinically manageable. However, the disease remains incurable, since it establishes latent …
clinically manageable. However, the disease remains incurable, since it establishes latent …
Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations
J Grau-Expósito, L Luque-Ballesteros, J Navarro… - PLoS …, 2019 - journals.plos.org
Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are
ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The …
ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The …